Mydecine Innovations Group (MYCO.C) announced that they were sponsoring a study called “The neurocognitive effects of low dose psychoactive substances,” at Macquary University in Australia today, according to a press release.
The research is on naturalistic microdosing in a lab setting, and it differs from previous studies in that it doesn’t rely on surveys of microdosers and includes people with a pre-established microdosing practice rather than focusing on people who haven’t microdosed before.
“Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition. In exploring the experiences of genuine microdosers from multiple angles, looking at behavioural, neuroimaging and biomarker data, we want to discover what actually happens when people microdose ‘in the wild’ and whether we can find objective indicators of some of the benefits that microdosers claim,” said Dr. Vince Polito, senior research fellow at the Department of Cognitive Science at Macquarie University
MYCO is presently trading at $0.385, down from $0.60 in late November.
“This study will further shed light on currently ambiguous effects of microdosing. Microdosing has a strong following of self-administering users, but actual medical data is currently thin. By applying scientific rigor like this, along with the ongoing work at the Imperial College London, we are helping to build a library of solid data sets that begin to tell us how microdosing works, and how it can be used in future clinical trials for various mental health issues,” said Josh Bartch, CEO and co-founder of Mydecine.
The study will use magnetoencephalography, or MEG scans, to pinpoint activity in the brain, as well as planned cognitive and biometric measures, while microdosing.